Trials / Completed
CompletedNCT00240292
Rosuvastatin Impact on Ventricular Remodelling Lipids and Cytokines
A Double-blind, Randomised, Placebo-controlled, Parallel-group, Multicentre, Phase III Study to Assess the Impact of Rosuvastatin Treatment for 26 Weeks (Titrated to a Maximum Dose of 40mg Once Daily) on Left Ventricular Function, Cytokines and Lipid Parameters in Patients With Established Systolic Chronic Heart Failure.
- Status
- Completed
- Phase
- Phase 3
- Study type
- Interventional
- Enrollment
- 160 (planned)
- Sponsor
- AstraZeneca · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
The purpose of this study is to assess the effect of rosuvastatin (up-titrated to a dose of 40mg/day) compared to placebo on cardiac remodelling, estimated by change in left ventricular ejection fraction on radionuclide ventriculography, at 26 weeks post randomisation from baseline.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Rosuvastatin |
Timeline
- Start date
- 2003-02-01
- First posted
- 2005-10-18
- Last updated
- 2010-11-19
Locations
13 sites across 1 country: Australia
Source: ClinicalTrials.gov record NCT00240292. Inclusion in this directory is not an endorsement.